76 results about "Therapeutic group" patented technology

The invention relates to the technical field of intelligent wearing monitoring, in particular to a multifunctional head-mounted device for improving anxiety and depression symptoms in the perioperative period, which comprises a main body base, an electric treatment assembly and a power supply assembly are arranged on the main body base, extending ear hooks are arranged at two ends of the main body base, binding straps are arranged on the extending ear hooks, and a nose pad block is arranged at the bottom of the main body base. The electric treatment assembly is in signal connection with an evaluation and control system, heart rate monitoring assemblies are arranged on the extension ear hooks, and an eye movement monitoring assembly is arranged at the bottom of the main body base; a displacement monitoring assembly is arranged on the main body base, and a respiration monitoring assembly is arranged on the nose pad block. According to the invention, physiological parameter monitoring, anxiety and depression assessment and percutaneous nerve stimulation treatment functions are integrated, and multi-node fixed design and real-time dynamic data processing are combined, so that redundant steps depending on preposed medical assessment in the traditional technology are omitted, doctors can remotely and accurately adjust personalized schemes based on dynamic data, and the accuracy of diagnosis and treatment is improved. The anxiety depression intervention efficiency and reliability in the perioperative period are improved.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are histotripsy and / or ultrasound transducer arrays, and associated systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. The transducer arrays provided herein can include a machined array shell having a plurality of wells formed therein. An acoustic stack including a plurality of matching and transducer elements can be disposed in the wells and be configured to transmit ultrasound energy through the plurality of matching layers and through the array shell towards a common focal point

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are histotripsy and / or ultrasound transducer arrays, and associated systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. The transducer arrays provided herein can be individually tuned such that transducer arrays with different sizes, focal lengths, or transducer element sizes may work at a desired operating frequency with the same signal generator.

Provided is a process including: accessing clinical trial data of an ongoing clinical trial that is not yet complete, the clinical trial having a plurality of treatment groups and a plurality of patients in the treatment groups; detecting, with an anomaly detection model, an anomaly in the clinical trial data for a first patient, the anomaly corresponding to a first patient among the plurality of patients; in response to detecting the anomaly classifying the first patient as anomalous in the trial; generating, with the computer system, by an artificial intelligence model, a candidate explanation for the detected anomaly by designating data in a record for the first patient as potentially correlated with the anomaly; and causing the anomaly and the candidate explanation to be presented to a data safety monitoring board (“DSMB”) of the clinical trial.

The invention discloses an application of rapamycin in preparation of a composition for treating a hereditary spastic paraplegia SPG subtype. The rapamycin can obviously improve the motion disorder and pathological injury phenotype of an SPG80 subtype mammal model, improve the lysosome function and promote the autophagy process through mTOR inhibition, provides specific intervention for nerve cell apoptosis and a glial cell abnormal activation mechanism caused by UBAP1 deletion, fills the blank that no effective treatment means exists for the SPG subtype, and has a good application prospect. A theoretical basis is provided for clinical treatment of patients, and a reference is provided for other SPG variations (such as SPG3A).

Apparatuses, systems, and methods for treating a tissue site. A system for treating a tissue site with negative pressure includes a dressing and a dressing interface. The dressing includes a cover configured to be disposed over the tissue site, a tissue interface configured to be positioned adjacent to the cover, and a wound contact layer configured to be positioned adjacent to the tissue interface. The dressing interface is configured to be coupled to the cover to fluidly couple the tissue interface and the wound contact layer to a therapy unit. The dressing interface is also configured to transmit electromagnetic radiation through the cover.

The invention provides cardiovascular intervention postoperative treatment equipment which structurally comprises a lying plate, a moving seat, a telescopic part, a positioning block and a treatment assembly, the lying plate is embedded in the upper middle area of the moving seat, the telescopic part is fixed to the lower middle area in front of the moving seat and is in interval fit with the lying plate, and the positioning block is fixedly connected with the other end of the telescopic part; the treatment assembly is arranged at the upper end of the positioning block and is horizontally communicated with the lying plate; after the lying plate is further improved, the inner side of the plate body is completely covered by the sponge cushion, so that the back bone of a patient can be prevented from being in direct contact with the plate body, and the pain caused by the influence of the hardness of the plate body on the back bone is prevented; then, the infrared positioner on the plate body can be matched with the top part of the treatment assembly in a light induction mode through the infrared generating body of the infrared positioner, so that the cardiovascular treatment area of the patient can be determined through infrared induction instead of medical staff, and therefore the position determination accuracy and efficiency can be improved.

The present disclosure provides therapeutic combinations, which provide a synergistic effect in treating a cancer. The present disclosure provides methods of treatment including administration of the combinations, and uses of the combinations, e.g., for treatment of cancer.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. The histotripsy therapy system can include a robotic positioning system configured to move and translate an ultrasound transducer array through a treatment volume.

The application discloses application of pentagalloyl glucose (PGG) in preparation of an anti-doxorubicin cardiotoxicity medicine. The process is as follows: a myocardial cell H9C2 injury model is induced and established by doxorubicin (DOX), and a minimum concentration of the myocardial cell injury induced by DOX is determined. After 20 muM of PGG is added to a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. A mouse myocardial injury model is induced and established by DOX, compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and the ejection fraction (EF%) of mice in the doxorubicin+pentagalloyl glucose group are significantly increased, the myocardial fiber structure is improved, cytoplasm vacuolization is reduced, the serum cTnT and BNP levels are reduced, and the ROS level is reduced. It is proved by the above experiments that the pentagalloyl glucose can significantly reduce DOX-induced myocardial toxicity.

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

An ergonomic and unobtrusive cardiac monitoring and treatment device with separable monitoring and treatment components includes a first wearable portion, a second wearable portion separable from the first wearable portion, and a device controller. The device controller includes at least one processor and an output device. The first wearable portion includes an elongated strap configured to encircle a thoracic region, ECG sensing electrodes permanently formed into the strap, a driven ground electrode, and conductive wires configured to couple the sensing electrodes with the controller. The second wearable portion includes a wearable substrate configured to be worn over at least one shoulder, one or more treatment electrodes configured to provide a therapeutic shock to the patient, and at least one additional conductive wire configured to releasably connect the treatment electrode(s) to the controller. The output device is configured to provide a notification instructing the patient to wear the second wearable portion.

A device may establish communication between the plurality of intelligent injection devices and an artificial intelligence-powered clinical research platform configured to manage a clinical trial or research program. A device may analyze, via the artificial intelligence platform, clinical trial protocol requirements including study design parameters, randomization schemes, blinding protocols, and adverse event monitoring requirements to generate coordinated medication administration strategies across the plurality of intelligent injection devices. A device may apply research protocol constraints to restrict medication selection, dosage calculations, administration timing, and patient assignment across the plurality of intelligent injection devices. A device may generate real-time coordination instructions through the artificial intelligence platform including synchronized administration timing across multiple sites, dosage verification protocols for different treatment arms, and compliance monitoring procedures tailored to specific research protocol requirements.

Conventional hospital management support systems are limited to a relative evaluation of patient attributes and medical departments, and do not accurately grasp the profitability and costs of each disease or treatment group. This makes it difficult to perform specific data analysis that directly leads to optimal allocation of medical resources, improved treatment efficiency, and management improvements. [Solution] This invention provides a "patient grouping management module" that groups patients based on specific treatments or diseases, and calculates and visualizes the profitability, costs, and profit margins of each group. Furthermore, by calculating management indicators for each patient group based on medical fees, drug price margins, and material margins, and visualizing and analyzing the results in real time, it builds a management support system that allows doctors and managers to specifically plan resource allocation and treatment strategies.

A therapy assembly can have an inner layer having an inner surface and an outer surface and defining a plurality of openings extending therethrough. The therapy assembly can also include a plurality of plates, each plate at least partially received within a respective opening of the plurality of openings of the inner layer. The therapy assembly can also include therapy circuitry including a cable having a plurality of electrical leads and a plurality of lead ends, each electrical lead electrically connected to a respective lead end of the plurality of lead ends. A cover layer can be attached to the outer surface of the inner layer and cover the plurality of lead ends of the cable. The plurality of lead ends can be in contact with a respective plate of the plurality of plates to define a plurality of electrodes.

To provide methods and compositions for preventing or treating (e.g., slowing the progression of, arresting and / or reversing) tissue calcification in a subject in need of the prevention or treatment of the tissue calcification.SOLUTION: The invention provides methods of using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7) for preventing or treating tissue calcification in a subject with diabetes, chronic kidney disease, end-stage renal failure, or a subject undergoing hemodialysis and / or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and / or menaquinol-7 (MKH2-7), for preventing or treating the one or more symptoms of COPD.SELECTED DRAWING: None

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features such as planning and implementation of an adaptive distribution of cooling periods across a treatment volume of tissue given various treatment depths and voltages. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures for tissue cooling. Other embodiments are described herein.

This invention discloses a seated rehabilitation training device, comprising a base, a seated platform mounted on the base, and a column mounted at each of the four corners of the base. Two sets of treatment components are slidably connected between adjacent columns. A top frame is mounted on the top of each column, and a traction component is mounted on the top frame. The treatment components include a mounting box, a push rod, a guide slider, and a push pillow. The traction component includes two parallel first pulleys, multiple spaced second pulleys, a traction rope, and a traction frame. An airbag device is connected to each column. This invention integrates three core rehabilitation functions—spinal traction, multi-directional mechanical compression, and airbag pressure therapy—into a single device. Patients can receive combined traction and multi-directional compression treatment sequentially or simultaneously on the same device and in the same posture, achieving synergistic therapeutic force and effectively overcoming the drawbacks of traditional therapies that require switching between different devices and fragmented treatment processes.

The application provides a polypeptide for specifically blocking the combination of ACVR1C and Grem1 and application thereof, and belongs to the technical field of biological medicine. The application finds a new combination of receptors of Grem1 and ACVR1C, and determines the combination sites of the two; then according to the details of the combination of Grem1 and ACVR1C, a specific blocking small molecule polypeptide (ACVR1C peptide) is designed. The small molecule polypeptide can interfere with or block the combination of Grem1 and ACVR1C in an in-vitro experiment; in an in-vivo treatment experiment, the liver metastasis of colon cancer of the treatment group mice is obviously lower than that of the control group, which indicates that the small molecule polypeptide reaches the target of blocking the liver metastasis of colon cancer by interfering with or blocking the combination of Grem1 and ACVR1C, and provides a new drug design and treatment target for relieving the liver metastasis of colon cancer.

A clinical trial support apparatus includes a processor, in which the processor predicts a progression speed of a target disease for subjects of a clinical trial, divides the subjects into a plurality of groups according to a prediction result of the progression speed of the target disease, and allocates the subjects to a treatment group to which a test drug is administered and a placebo group to which a placebo is administered for each of the plurality of groups.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are systems and methods for acoustically coupling a histotripsy therapy system to the skin of a patient to provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures.

The application discloses application of hydroxyl genkwa flower ketone (HGK) in preparation of a medicine for preventing and treating cardiotoxicity induced by an anti-tumor medicine. The process is as follows: a doxorubicin (DOX) is used to induce and establish a myocardial cell H9C2 injury model, and a minimum concentration of the myocardial cell injury induced by the DOX is determined. After 20 muM of the HGK is added to a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. The DOX is used to induce and establish a mouse myocardial injury model, compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and the ejection fraction (EF%) of mice in the doxorubicin+hydroxyl genkwa flower ketone group are significantly increased, the myocardial fiber structure is improved, the cytoplasm vacuolization is reduced, the serum cTnT, CK-MB and BNP levels are reduced, and the heart tissue ROS level is reduced. Therefore, the hydroxyl genkwa flower ketone can significantly reduce the myocardial toxicity induced by the DOX.

The present application relates to a kind of humanized BCMA antibody and its application.The present application designs whole humanization antibody to BCMA target point, the antibody can be highly specific binding human source BCMA protein, based on this antibody constructs chimeric antigen receptor, prepares CAR-T cell, and experiment proves that, CAR-T cell can be efficiently recognized and kill BCMA positive tumor cell in in vitro and in vivo model, significantly inhibit tumor growth proliferation.In tumor-bearing mouse model, the survival time of treatment group mice is significantly prolonged, indicating that the antibody and the CAR therapy derived from the application have clear targeted therapy effect on the related diseases with BCMA as target point.

The invention provides non-opioid pain therapeutic compositions that include an antisense oligonucleotide (ASO) complementary to an identified target on a NaV channel mRNA. The ASO hybridizes to its target RNA and forms a duplex that recruits RNase H to degrade the RNA, thereby downregulating NaV channel synthesis, which inhibits the neuron's ability to contribute to the perception of pain. The ASO targets one of the specific identified targets, and may be provided as a gapmer that includes a central DNA segment flanked by modified RNA wings. When the composition is delivered to dorsal root ganglion (DRG) neurons in vitro, the DRG neurons exhibit a dose-dependent knockdown of NaV1.7, NaV1.8, or NaV1.9.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures.

Disclosed are therapeutic combinations for eliciting an entactogenic mindstate, such as through use of compositions comprising imidazoline receptor agents, cannabinoid receptor agents, and / or serotonin receptor agents. Also disclosed are certain selective receptor agents, pharmaceutical compositions thereof, and methods for their use to treat mental health conditions, improve mental health and mental functioning, and design and create entactogenic mental states or mindstates.

Disclosed herein are capped RNA molecules comprising one or more modified nucleotides at position +3 or higher with reference to a 5' terminus of the RNA molecule, and methods of making the same. The capped RNA molecules may be made by ligating a 5'-capped modified RNA oligonucleotide to the 3' terminus of an RNA molecule. Also provided are compositions comprising one or more of the capped RNA molecules provided herein, and methods of using said compositions for therapeutic applications, such as in the treatment or prevention of a disease in a subject, such as SARS-CoV-2.

A system for delivering a therapeutic composition to a patient, the system including: a container configured to hold the therapeutic composition; at least one powered driver operatively connected to the container; a plurality of sensors including at least two of: (i) a pressure sensor, (ii) a flow sensor, (iii) a counting sensor, (iv) a site sensor, (v) a temperature sensor, (vi) a chemical sensor, and (vii) at least one physiological sensor; and at least one processor programmed or configured to receive data from the plurality of sensors and control the at least one powered driver to infuse the therapeutic composition into the patient at a desired flow rate, the magnitude of which is dependent on the data received from the plurality of sensors.